A translational, caffeine-induced model of onset insomnia in rats and healthy volunteers
Insomnia is a common and disabling complaint for which there is a need for improved treatments. Successful drug discovery relies on the use of appropriate animal models to assess likely outcome in the clinic. The purpose of this study was to develop a translational, caffeine-induced model of insomni...
Saved in:
Published in | Psychopharmacologia Vol. 191; no. 4; pp. 943 - 950 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Berlin
Springer
01.05.2007
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Insomnia is a common and disabling complaint for which there is a need for improved treatments. Successful drug discovery relies on the use of appropriate animal models to assess likely outcome in the clinic.
The purpose of this study was to develop a translational, caffeine-induced model of insomnia in rats and healthy volunteers. We used sleep onset latency (SOL) as a comparable sleep measure between the two species. The model was validated by two effective sleep-promoting agents with different pharmacology, zolpidem and trazodone, which have GABA-ergic and serotonergic mechanisms, respectively.
In rats, radiotelemetry transmitters with electroencephalogram and electromyogram electrodes were implanted for sleep recording. Animals were administered with caffeine alone (10 mg/kg) or in combination with zolpidem (10 mg/kg) or trazodone (20 mg/kg), or vehicle, in crossover experiments. Home polysomnography was performed in 12 healthy male volunteers in a randomised, placebo-controlled, 4-week crossover study. Subjects received placebo, caffeine (150 mg) or caffeine in combination with zolpidem (10 mg) or trazodone (100 mg). Subjective sleep effects in volunteers were assessed using the Leeds Sleep Evaluation Questionnaire.
Caffeine caused a significant prolongation in objective SOL in rats and humans. This effect was sensitive to zolpidem and trazodone, both of which attenuated the caffeine-induced increase in SOL. Furthermore, both hypnotics restored the disruption in subjective measures of sleep onset caused by caffeine in volunteers.
This model therefore provides a promising paradigm in which we can study novel treatments for sleep disorders and an opportunity for direct comparison of results between rodents and humans. |
---|---|
AbstractList | Rationale: Insomnia is a common and disabling complaint for which there is a need for improved treatments. Successful drug discovery relies on the use of appropriate animal models to assess likely outcome in the clinic. Objectives: The purpose of this study was to develop a translational, caffeine-induced model of insomnia in rats and healthy volunteers. We used sleep onset latency (SOL) as a comparable sleep measure between the two species. The model was validated by two effective sleep-promoting agents with different pharmacology, zolpidem and trazodone, which have GABA-ergic and serotonergic mechanisms, respectively. Materials and methods: In rats, radiotelemetry transmitters with electroencephalogram and electromyogram electrodes were implanted for sleep recording. Animals were administered with caffeine alone (10 mg/kg) or in combination with zolpidem (10 mg/kg) or trazodone (20 mg/kg), or vehicle, in crossover experiments. Home polysomnography was performed in 12 healthy male volunteers in a randomised, placebo-controlled, 4-week crossover study. Subjects received placebo, caffeine (150 mg) or caffeine in combination with zolpidem (10 mg) or trazodone (100 mg). Subjective sleep effects in volunteers were assessed using the Leeds Sleep Evaluation Questionnaire. Results: Caffeine caused a significant prolongation in objective SOL in rats and humans. This effect was sensitive to zolpidem and trazodone, both of which attenuated the caffeine-induced increase in SOL. Furthermore, both hypnotics restored the disruption in subjective measures of sleep onset caused by caffeine in volunteers. Conclusions: This model therefore provides a promising paradigm in which we can study novel treatments for sleep disorders and an opportunity for direct comparison of results between rodents and humans. Insomnia is a common and disabling complaint for which there is a need for improved treatments. Successful drug discovery relies on the use of appropriate animal models to assess likely outcome in the clinic.RATIONALEInsomnia is a common and disabling complaint for which there is a need for improved treatments. Successful drug discovery relies on the use of appropriate animal models to assess likely outcome in the clinic.The purpose of this study was to develop a translational, caffeine-induced model of insomnia in rats and healthy volunteers. We used sleep onset latency (SOL) as a comparable sleep measure between the two species. The model was validated by two effective sleep-promoting agents with different pharmacology, zolpidem and trazodone, which have GABA-ergic and serotonergic mechanisms, respectively.OBJECTIVESThe purpose of this study was to develop a translational, caffeine-induced model of insomnia in rats and healthy volunteers. We used sleep onset latency (SOL) as a comparable sleep measure between the two species. The model was validated by two effective sleep-promoting agents with different pharmacology, zolpidem and trazodone, which have GABA-ergic and serotonergic mechanisms, respectively.In rats, radiotelemetry transmitters with electroencephalogram and electromyogram electrodes were implanted for sleep recording. Animals were administered with caffeine alone (10 mg/kg) or in combination with zolpidem (10 mg/kg) or trazodone (20 mg/kg), or vehicle, in crossover experiments. Home polysomnography was performed in 12 healthy male volunteers in a randomised, placebo-controlled, 4-week crossover study. Subjects received placebo, caffeine (150 mg) or caffeine in combination with zolpidem (10 mg) or trazodone (100 mg). Subjective sleep effects in volunteers were assessed using the Leeds Sleep Evaluation Questionnaire.MATERIALS AND METHODSIn rats, radiotelemetry transmitters with electroencephalogram and electromyogram electrodes were implanted for sleep recording. Animals were administered with caffeine alone (10 mg/kg) or in combination with zolpidem (10 mg/kg) or trazodone (20 mg/kg), or vehicle, in crossover experiments. Home polysomnography was performed in 12 healthy male volunteers in a randomised, placebo-controlled, 4-week crossover study. Subjects received placebo, caffeine (150 mg) or caffeine in combination with zolpidem (10 mg) or trazodone (100 mg). Subjective sleep effects in volunteers were assessed using the Leeds Sleep Evaluation Questionnaire.Caffeine caused a significant prolongation in objective SOL in rats and humans. This effect was sensitive to zolpidem and trazodone, both of which attenuated the caffeine-induced increase in SOL. Furthermore, both hypnotics restored the disruption in subjective measures of sleep onset caused by caffeine in volunteers.RESULTSCaffeine caused a significant prolongation in objective SOL in rats and humans. This effect was sensitive to zolpidem and trazodone, both of which attenuated the caffeine-induced increase in SOL. Furthermore, both hypnotics restored the disruption in subjective measures of sleep onset caused by caffeine in volunteers.This model therefore provides a promising paradigm in which we can study novel treatments for sleep disorders and an opportunity for direct comparison of results between rodents and humans.CONCLUSIONSThis model therefore provides a promising paradigm in which we can study novel treatments for sleep disorders and an opportunity for direct comparison of results between rodents and humans. Insomnia is a common and disabling complaint for which there is a need for improved treatments. Successful drug discovery relies on the use of appropriate animal models to assess likely outcome in the clinic. The purpose of this study was to develop a translational, caffeine-induced model of insomnia in rats and healthy volunteers. We used sleep onset latency (SOL) as a comparable sleep measure between the two species. The model was validated by two effective sleep-promoting agents with different pharmacology, zolpidem and trazodone, which have GABA-ergic and serotonergic mechanisms, respectively. In rats, radiotelemetry transmitters with electroencephalogram and electromyogram electrodes were implanted for sleep recording. Animals were administered with caffeine alone (10 mg/kg) or in combination with zolpidem (10 mg/kg) or trazodone (20 mg/kg), or vehicle, in crossover experiments. Home polysomnography was performed in 12 healthy male volunteers in a randomised, placebo-controlled, 4-week crossover study. Subjects received placebo, caffeine (150 mg) or caffeine in combination with zolpidem (10 mg) or trazodone (100 mg). Subjective sleep effects in volunteers were assessed using the Leeds Sleep Evaluation Questionnaire. Caffeine caused a significant prolongation in objective SOL in rats and humans. This effect was sensitive to zolpidem and trazodone, both of which attenuated the caffeine-induced increase in SOL. Furthermore, both hypnotics restored the disruption in subjective measures of sleep onset caused by caffeine in volunteers. This model therefore provides a promising paradigm in which we can study novel treatments for sleep disorders and an opportunity for direct comparison of results between rodents and humans. Rationale Insomnia is a common and disabling complaint for which there is a need for improved treatments. Successful drug discovery relies on the use of appropriate animal models to assess likely outcome in the clinic. Objectives The purpose of this study was to develop a translational, caffeine-induced model of insomnia in rats and healthy volunteers. We used sleep onset latency (SOL) as a comparable sleep measure between the two species. The model was validated by two effective sleep-promoting agents with different pharmacology, zolpidem and trazodone, which have GABA-ergic and serotonergic mechanisms, respectively. Materials and methods In rats, radiotelemetry transmitters with electroencephalogram and electromyogram electrodes were implanted for sleep recording. Animals were administered with caffeine alone (10 mg/kg) or in combination with zolpidem (10 mg/kg) or trazodone (20 mg/kg), or vehicle, in crossover experiments. Home polysomnography was performed in 12 healthy male volunteers in a randomised, placebo-controlled, 4-week crossover study. Subjects received placebo, caffeine (150 mg) or caffeine in combination with zolpidem (10 mg) or trazodone (100 mg). Subjective sleep effects in volunteers were assessed using the Leeds Sleep Evaluation Questionnaire. Results Caffeine caused a significant prolongation in objective SOL in rats and humans. This effect was sensitive to zolpidem and trazodone, both of which attenuated the caffeine-induced increase in SOL. Furthermore, both hypnotics restored the disruption in subjective measures of sleep onset caused by caffeine in volunteers. Conclusions This model therefore provides a promising paradigm in which we can study novel treatments for sleep disorders and an opportunity for direct comparison of results between rodents and humans. [PUBLICATION ABSTRACT] |
Author | Hutson, Peter H. Wilson, Sue J. Nutt, David J. Ivarsson, Magnus Paterson, Louise M. |
Author_xml | – sequence: 1 givenname: Louise M. surname: Paterson fullname: Paterson, Louise M. – sequence: 2 givenname: Sue J. surname: Wilson fullname: Wilson, Sue J. – sequence: 3 givenname: David J. surname: Nutt fullname: Nutt, David J. – sequence: 4 givenname: Peter H. surname: Hutson fullname: Hutson, Peter H. – sequence: 5 givenname: Magnus surname: Ivarsson fullname: Ivarsson, Magnus |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18677076$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/17225163$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkU1rFTEUhoNU7G31B7iRIOjK0ZNkJsksS_ELCm4U3IUz-aApmaROZgr99-Z6rxS60GxOFs85nPM-Z-Qkl-wJecngPQNQHyoAZ6IDkB1IxTt4QnasF7zjoPgJ2QEI0Qk26FNyVusNtNfr_hk5ZYrzgUmxIz8v6LpgrgnXWDKmd9RiCD5m38XsNusdnYvziZZAS65-pTHXMueI7UMXXCvF7Oi1x7Re39O7kra8er_U5-RpwFT9i2M9Jz8-ffx--aW7-vb56-XFVWf7QaxdcEKKSbKg0bpeSfCIY7st8DAqpwPiNLhJg5jGaXJOcRuGAAiDCJox68Q5eXuYe7uUX5uvq5ljtT4lzL5s1SjgUiot_guyUfagBTTw9SPwpmxLy6YazvQ4SA77aa-O0DbN3pnbJc643Ju_yTbgzRHAajGFFrKN9YHTUilQsnHswNml1Lr48ICA2Vs2B8umWTZ7y2a_oXrUY-P6R2BzGdM_On8DdnGqxg |
CODEN | PSYPAG |
CitedBy_id | crossref_primary_10_3390_nu15041042 crossref_primary_10_1177_0748730418789236 crossref_primary_10_1523_JNEUROSCI_1809_08_2008 crossref_primary_10_1089_jcr_2011_0030 crossref_primary_10_1177_2165079915579561 crossref_primary_10_1248_bpb_b19_00454 crossref_primary_10_1016_j_jsmc_2019_01_007 crossref_primary_10_1016_j_yrtph_2015_12_002 crossref_primary_10_1155_2018_7196142 crossref_primary_10_1177_14727978241299575 crossref_primary_10_1039_C9RA01549C crossref_primary_10_3390_nu11030556 crossref_primary_10_1016_j_ejphar_2014_09_012 crossref_primary_10_1177_0269881109104852 crossref_primary_10_1093_sleep_zsad112 crossref_primary_10_1186_1753_4631_5_4 crossref_primary_10_4062_biomolther_2016_156 crossref_primary_10_1016_j_pnpbp_2015_05_006 crossref_primary_10_1038_s41401_024_01269_w crossref_primary_10_1177_0269881111400643 crossref_primary_10_3390_nu14112249 crossref_primary_10_1177_0269881110379307 crossref_primary_10_1016_j_neubiorev_2009_03_002 crossref_primary_10_1111_j_1601_183X_2011_00719_x crossref_primary_10_1111_j_1747_0080_2012_01601_x crossref_primary_10_1016_j_fitote_2014_04_017 crossref_primary_10_1586_ecp_10_138 crossref_primary_10_1111_bph_12782 crossref_primary_10_12968_hmed_2009_70_6_327 crossref_primary_10_4162_nrp_2018_12_3_208 crossref_primary_10_1177_09645284211011489 crossref_primary_10_1016_j_fct_2017_04_002 crossref_primary_10_1177_0960327118769717 crossref_primary_10_1016_j_pbb_2012_01_011 crossref_primary_10_1177_0269881109104846 crossref_primary_10_1016_j_jfda_2016_05_005 crossref_primary_10_3390_bs8080065 |
Cites_doi | 10.1016/j.ejphar.2004.09.054 10.1046/j.1460-9568.1998.00069.x 10.1097/00004714-199006000-00005 10.1002/j.1875-9114.1982.tb03193.x 10.1016/j.ejphar.2005.08.050 10.1016/1043-6618(94)80002-2 10.1046/j.1440-1819.1998.00403.x 10.1016/S0165-0270(02)00148-6 10.1007/BF00432545 10.1016/S0014-2999(02)02915-1 10.1007/BF02244546 10.1016/S0091-3057(97)00595-9 10.1001/jama.1997.03550240060035 10.1002/hup.470030104 10.1016/S0006-8993(02)02698-7 10.1016/S0149-2918(00)83043-X 10.1002/hup.445 10.1017/S0033291700014379 10.1177/026988110001400420 10.1016/S0021-9673(00)97841-5 10.1016/0014-2999(96)00021-0 10.1002/(SICI)1099-1077(199605)11:3<185::AID-HUP786>3.0.CO;2-M 10.4088/JCP.v66n0409 10.1002/(SICI)1099-1077(199804)13:3<191::AID-HUP972>3.0.CO;2-X 10.1111/j.1365-2125.1983.tb04977.x 10.1016/S0924-9338(99)80736-6 10.1016/j.brainres.2005.08.015 10.1097/00004714-199504000-00009 10.1093/sleep/27.3.536 10.1007/s002130000383 10.1093/sleep/22.1.33 10.1016/j.clpt.2003.11.375 10.1002/cpt1976206682 |
ContentType | Journal Article |
Copyright | 2007 INIST-CNRS Springer-Verlag 2007 |
Copyright_xml | – notice: 2007 INIST-CNRS – notice: Springer-Verlag 2007 |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7QG 7QR 7RV 7TK 7X7 7XB 88E 88G 8AO 8FD 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ K9. KB0 M0S M1P M2M NAPCQ P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PSYQQ Q9U 7U7 C1K 7X8 |
DOI | 10.1007/s00213-006-0672-0 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Animal Behavior Abstracts Chemoreception Abstracts Nursing & Allied Health Database Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) ProQuest Pharma Collection Technology Research Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Engineering Research Database Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Psychology Database Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic Toxicology Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology ProQuest Central Student Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection Chemoreception Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition Animal Behavior Abstracts ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) Toxicology Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | Toxicology Abstracts MEDLINE - Academic MEDLINE ProQuest One Psychology |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1432-2072 |
EndPage | 950 |
ExternalDocumentID | 1231721161 17225163 18677076 10_1007_s00213_006_0672_0 |
Genre | Validation Studies Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | .55 3SX 40D 40E 95. 95~ AAYXX ABMNI AGWIL ALMA_UNASSIGNED_HOLDINGS CITATION KOW N2Q R9- RHV SBY SOJ X7M ~EX IQODW -4W -BR CGR CUY CVF ECM EIF NPM 3V. 7QG 7QR 7RV 7TK 7X7 7XB 88E 8AO 8FD 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FR3 FYUFA GNUQQ K9. M1P M2M NAPCQ P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PSYQQ Q9U 7U7 C1K 7X8 |
ID | FETCH-LOGICAL-c453t-fd363b61f8acd4760eaa9007f2f97d8faab5db803b9bbdd72cf5f0a053f811cd3 |
IEDL.DBID | 7X7 |
ISSN | 0033-3158 |
IngestDate | Fri Jul 11 06:03:33 EDT 2025 Thu Jul 10 18:14:44 EDT 2025 Sun Aug 17 12:10:56 EDT 2025 Sat Sep 28 07:57:22 EDT 2024 Wed Apr 02 07:25:59 EDT 2025 Thu Apr 24 23:04:59 EDT 2025 Tue Jul 01 04:16:30 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | Agonist Telemetry·Caffeine·Zolpidem· Trazodone Sleep Rat Psychotropic Benzodiazepine receptor Trazodone Bicyclic compound Antidepressant agent Xanthine derivatives Neurological disorder Caffeine Human Nervous system diseases Healthy subject CNS stimulant Gabaergic agonist Rodentia Sleep disorder Hypnotic Polysomnography Vertebrata Mammalia Sleep Tranquillizer Insomnia Animal Zolpidem Models Piperazine derivatives Gabaergic receptor A Healthy volunteer- Rat |
Language | English |
License | http://www.springer.com/tdm CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c453t-fd363b61f8acd4760eaa9007f2f97d8faab5db803b9bbdd72cf5f0a053f811cd3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
PMID | 17225163 |
PQID | 218956203 |
PQPubID | 47309 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_70266783 proquest_miscellaneous_19640830 proquest_journals_218956203 pubmed_primary_17225163 pascalfrancis_primary_18677076 crossref_primary_10_1007_s00213_006_0672_0 crossref_citationtrail_10_1007_s00213_006_0672_0 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2007-05-01 |
PublicationDateYYYYMMDD | 2007-05-01 |
PublicationDate_xml | – month: 05 year: 2007 text: 2007-05-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Berlin |
PublicationPlace_xml | – name: Berlin – name: Germany – name: Heidelberg |
PublicationTitle | Psychopharmacologia |
PublicationTitleAlternate | Psychopharmacology (Berl) |
PublicationYear | 2007 |
Publisher | Springer Springer Nature B.V |
Publisher_xml | – name: Springer – name: Springer Nature B.V |
References | R Cluydts (672_CR5) 1995; 15 AC Parrott (672_CR28) 1978; 8 CA Haller (672_CR12) 2004; 75 D Drover (672_CR7) 2000; 22 V Vogel (672_CR34) 2002; 118 A Rechtschaffen (672_CR30) 1968 K Shinomiya (672_CR33) 2004; 504 MH Bonnet (672_CR2) 1992; 15 JK Walsh (672_CR35) 1990; 10 I Montgomery (672_CR22) 1983; 16 JK Walsh (672_CR36) 1998; 13 Y Wang (672_CR37) 1998; 60 SJ Wilson (672_CR38) 2000; 14 M Ivarsson (672_CR16) 2005; 522 C Gottesmann (672_CR10) 1998; 10 B Schwierin (672_CR31) 1996; 300 WB Mendelson (672_CR21) 2005; 66 I Hindmarch (672_CR13) 1988; 3 I Hindmarch (672_CR14) 2000; 149 A Georgotas (672_CR9) 1982; 2 D Garrigou-Gadenne (672_CR8) 1989; 248 PM Haffmans (672_CR11) 1999; 14 MJ Owens (672_CR27) 1997; 283 S Caccia (672_CR4) 1981; 210 A Rabat (672_CR29) 2005; 1059 S Kantor (672_CR17) 2002; 943 H Depoortere (672_CR6) 1986; 237 DP Brunner (672_CR3) 1991; 104 M Lancel (672_CR19) 1999; 22 C Iber (672_CR15) 2004; 27 CA Alford (672_CR1) 1996; 11 J Montplaisir (672_CR23) 2003; 18 K Shinomiya (672_CR32) 2003; 460 Z Lelkes (672_CR20) 1994; 30 PD Nowell (672_CR25) 1997; 278 672_CR24 H Yamadera (672_CR39) 1998; 52 I Karacan (672_CR18) 1976; 20 T Okuma (672_CR26) 1982; 76 9766695 - Psychiatry Clin Neurosci. 1998 Aug;52(4):439-43 9749703 - Eur J Neurosci. 1998 Feb;10(2):409-14 2871178 - J Pharmacol Exp Ther. 1986 May;237(2):649-58 12559374 - Eur J Pharmacol. 2003 Jan 24;460(2-3):139-44 11192136 - Clin Ther. 2000 Dec;22(12 ):1443-61 10572343 - Eur Psychiatry. 1999 Jun;14(3):167-71 6763207 - Pharmacotherapy. 1982 Sep-Oct;2(5):255-65 7816739 - Pharmacol Res. 1994 Aug-Sep;30(2):105-15 6615688 - Br J Clin Pharmacol. 1983 Aug;16(2):139-44 7782486 - J Clin Psychopharmacol. 1995 Apr;15(2):132-7 9417012 - JAMA. 1997 Dec 24-31;278(24):2170-7 9400006 - J Pharmacol Exp Ther. 1997 Dec;283(3):1305-22 11198056 - J Psychopharmacol. 2000;14(4):378-86 8739204 - Eur J Pharmacol. 1996 Apr 11;300(3):163-71 1881993 - Psychopharmacology (Berl). 1991;104(1):1-5 12532313 - Hum Psychopharmacol. 2003 Jan;18(1):29-38 2198296 - J Clin Psychopharmacol. 1990 Jun;10(3):184-9 9610952 - Pharmacol Biochem Behav. 1998 May;60(1):271-8 7263792 - J Chromatogr. 1981 Jun 5;210(2):311-8 15060505 - Clin Pharmacol Ther. 2004 Apr;75(4):259-73 15164911 - Sleep. 2004 May 1;27(3):536-40 15541420 - Eur J Pharmacol. 2004 Nov 19;504(3):185-9 2703975 - J Pharmacol Exp Ther. 1989 Mar;248(3):1283-8 9989364 - Sleep. 1999 Feb 1;22(1):33-42 16168393 - Brain Res. 2005 Oct 12;1059(1):72-82 12088844 - Brain Res. 2002 Jul 5;943(1):105-11 26096 - Psychol Med. 1978 May;8(2):325-9 6124991 - Psychopharmacology (Berl). 1982;76(3):201-8 10823400 - Psychopharmacology (Berl). 2000 Apr;149(3):203-16 16223479 - Eur J Pharmacol. 2005 Oct 17;522(1-3):63-71 1475567 - Sleep. 1992 Dec;15(6):526-36 12191761 - J Neurosci Methods. 2002 Jul 30;118(1):89-96 15816789 - J Clin Psychiatry. 2005 Apr;66(4):469-76 186223 - Clin Pharmacol Ther. 1976 Dec;20(6):682-9 |
References_xml | – volume: 504 start-page: 185 year: 2004 ident: 672_CR33 publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2004.09.054 – volume: 10 start-page: 409 year: 1998 ident: 672_CR10 publication-title: Eur J Neurosci doi: 10.1046/j.1460-9568.1998.00069.x – volume: 10 start-page: 184 year: 1990 ident: 672_CR35 publication-title: J Clin Psychopharmacol doi: 10.1097/00004714-199006000-00005 – volume: 2 start-page: 255 year: 1982 ident: 672_CR9 publication-title: Pharmacotherapy doi: 10.1002/j.1875-9114.1982.tb03193.x – volume: 522 start-page: 63 issue: 1–3 year: 2005 ident: 672_CR16 publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2005.08.050 – volume: 30 start-page: 105 year: 1994 ident: 672_CR20 publication-title: Pharmacol Res doi: 10.1016/1043-6618(94)80002-2 – volume: 237 start-page: 649 year: 1986 ident: 672_CR6 publication-title: J Pharmacol Exp Ther – volume: 52 start-page: 439 year: 1998 ident: 672_CR39 publication-title: Psychiatry Clin Neurosci doi: 10.1046/j.1440-1819.1998.00403.x – volume: 118 start-page: 89 issue: 1 year: 2002 ident: 672_CR34 publication-title: J Neurosci Methods doi: 10.1016/S0165-0270(02)00148-6 – volume: 76 start-page: 201 year: 1982 ident: 672_CR26 publication-title: Psychopharmacology (Berl) doi: 10.1007/BF00432545 – volume: 460 start-page: 139 year: 2003 ident: 672_CR32 publication-title: Eur J Pharmacol doi: 10.1016/S0014-2999(02)02915-1 – volume: 104 start-page: 1 issue: 1 year: 1991 ident: 672_CR3 publication-title: Psychopharmacology (Berl) doi: 10.1007/BF02244546 – volume: 60 start-page: 271 year: 1998 ident: 672_CR37 publication-title: Pharmacol Biochem Behav doi: 10.1016/S0091-3057(97)00595-9 – volume: 278 start-page: 2170 year: 1997 ident: 672_CR25 publication-title: JAMA doi: 10.1001/jama.1997.03550240060035 – volume: 3 start-page: 13 year: 1988 ident: 672_CR13 publication-title: Hum Psychopharmacol Clin Exp doi: 10.1002/hup.470030104 – volume: 943 start-page: 105 year: 2002 ident: 672_CR17 publication-title: Brain Res doi: 10.1016/S0006-8993(02)02698-7 – volume: 22 start-page: 1443 year: 2000 ident: 672_CR7 publication-title: Clin Ther doi: 10.1016/S0149-2918(00)83043-X – volume: 18 start-page: 29 year: 2003 ident: 672_CR23 publication-title: Hum Psychopharmacol doi: 10.1002/hup.445 – volume: 8 start-page: 325 year: 1978 ident: 672_CR28 publication-title: Psychol Med doi: 10.1017/S0033291700014379 – volume: 14 start-page: 378 year: 2000 ident: 672_CR38 publication-title: J Psychopharmacol doi: 10.1177/026988110001400420 – volume: 210 start-page: 311 year: 1981 ident: 672_CR4 publication-title: J Chromatogr doi: 10.1016/S0021-9673(00)97841-5 – volume: 283 start-page: 1305 year: 1997 ident: 672_CR27 publication-title: J Pharmacol Exp Ther – volume: 300 start-page: 163 year: 1996 ident: 672_CR31 publication-title: Eur J Pharmacol doi: 10.1016/0014-2999(96)00021-0 – volume: 11 start-page: 185 year: 1996 ident: 672_CR1 publication-title: Hum Psychopharmacol Clin Exp doi: 10.1002/(SICI)1099-1077(199605)11:3<185::AID-HUP786>3.0.CO;2-M – volume: 66 start-page: 469 year: 2005 ident: 672_CR21 publication-title: J Clin Psychiatry doi: 10.4088/JCP.v66n0409 – volume: 13 start-page: 191 year: 1998 ident: 672_CR36 publication-title: Hum Psychopharmacol doi: 10.1002/(SICI)1099-1077(199804)13:3<191::AID-HUP972>3.0.CO;2-X – ident: 672_CR24 – volume-title: A manual of standardised terminology: techniques and scoring system for sleep stages of human subjects year: 1968 ident: 672_CR30 – volume: 248 start-page: 1283 year: 1989 ident: 672_CR8 publication-title: J Pharmacol Exp Ther – volume: 16 start-page: 139 year: 1983 ident: 672_CR22 publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.1983.tb04977.x – volume: 14 start-page: 167 year: 1999 ident: 672_CR11 publication-title: Eur Psychiatry doi: 10.1016/S0924-9338(99)80736-6 – volume: 1059 start-page: 72 year: 2005 ident: 672_CR29 publication-title: Brain Res doi: 10.1016/j.brainres.2005.08.015 – volume: 15 start-page: 526 year: 1992 ident: 672_CR2 publication-title: Sleep – volume: 15 start-page: 132 year: 1995 ident: 672_CR5 publication-title: J Clin Psychopharmacol doi: 10.1097/00004714-199504000-00009 – volume: 27 start-page: 536 year: 2004 ident: 672_CR15 publication-title: Sleep doi: 10.1093/sleep/27.3.536 – volume: 149 start-page: 203 year: 2000 ident: 672_CR14 publication-title: Psychopharmacology (Berl) doi: 10.1007/s002130000383 – volume: 22 start-page: 33 year: 1999 ident: 672_CR19 publication-title: Sleep doi: 10.1093/sleep/22.1.33 – volume: 75 start-page: 259 year: 2004 ident: 672_CR12 publication-title: Clin Pharmacol Ther doi: 10.1016/j.clpt.2003.11.375 – volume: 20 start-page: 682 issue: 6 year: 1976 ident: 672_CR18 publication-title: Clin Pharmacol Ther doi: 10.1002/cpt1976206682 – reference: 9610952 - Pharmacol Biochem Behav. 1998 May;60(1):271-8 – reference: 12532313 - Hum Psychopharmacol. 2003 Jan;18(1):29-38 – reference: 6615688 - Br J Clin Pharmacol. 1983 Aug;16(2):139-44 – reference: 12191761 - J Neurosci Methods. 2002 Jul 30;118(1):89-96 – reference: 15164911 - Sleep. 2004 May 1;27(3):536-40 – reference: 1475567 - Sleep. 1992 Dec;15(6):526-36 – reference: 15541420 - Eur J Pharmacol. 2004 Nov 19;504(3):185-9 – reference: 12088844 - Brain Res. 2002 Jul 5;943(1):105-11 – reference: 2703975 - J Pharmacol Exp Ther. 1989 Mar;248(3):1283-8 – reference: 15060505 - Clin Pharmacol Ther. 2004 Apr;75(4):259-73 – reference: 15816789 - J Clin Psychiatry. 2005 Apr;66(4):469-76 – reference: 11192136 - Clin Ther. 2000 Dec;22(12 ):1443-61 – reference: 10823400 - Psychopharmacology (Berl). 2000 Apr;149(3):203-16 – reference: 7782486 - J Clin Psychopharmacol. 1995 Apr;15(2):132-7 – reference: 10572343 - Eur Psychiatry. 1999 Jun;14(3):167-71 – reference: 26096 - Psychol Med. 1978 May;8(2):325-9 – reference: 2198296 - J Clin Psychopharmacol. 1990 Jun;10(3):184-9 – reference: 7263792 - J Chromatogr. 1981 Jun 5;210(2):311-8 – reference: 16168393 - Brain Res. 2005 Oct 12;1059(1):72-82 – reference: 16223479 - Eur J Pharmacol. 2005 Oct 17;522(1-3):63-71 – reference: 9417012 - JAMA. 1997 Dec 24-31;278(24):2170-7 – reference: 9766695 - Psychiatry Clin Neurosci. 1998 Aug;52(4):439-43 – reference: 11198056 - J Psychopharmacol. 2000;14(4):378-86 – reference: 9400006 - J Pharmacol Exp Ther. 1997 Dec;283(3):1305-22 – reference: 6763207 - Pharmacotherapy. 1982 Sep-Oct;2(5):255-65 – reference: 186223 - Clin Pharmacol Ther. 1976 Dec;20(6):682-9 – reference: 2871178 - J Pharmacol Exp Ther. 1986 May;237(2):649-58 – reference: 9989364 - Sleep. 1999 Feb 1;22(1):33-42 – reference: 6124991 - Psychopharmacology (Berl). 1982;76(3):201-8 – reference: 7816739 - Pharmacol Res. 1994 Aug-Sep;30(2):105-15 – reference: 9749703 - Eur J Neurosci. 1998 Feb;10(2):409-14 – reference: 1881993 - Psychopharmacology (Berl). 1991;104(1):1-5 – reference: 12559374 - Eur J Pharmacol. 2003 Jan 24;460(2-3):139-44 – reference: 8739204 - Eur J Pharmacol. 1996 Apr 11;300(3):163-71 |
SSID | ssj0000484 ssj0068394 |
Score | 2.0596616 |
Snippet | Insomnia is a common and disabling complaint for which there is a need for improved treatments. Successful drug discovery relies on the use of appropriate... Rationale Insomnia is a common and disabling complaint for which there is a need for improved treatments. Successful drug discovery relies on the use of... Rationale: Insomnia is a common and disabling complaint for which there is a need for improved treatments. Successful drug discovery relies on the use of... |
SourceID | proquest pubmed pascalfrancis crossref |
SourceType | Aggregation Database Index Database Enrichment Source |
StartPage | 943 |
SubjectTerms | Adult Animals Biological and medical sciences Caffeine Central Nervous System Stimulants Clinical trials Comparative analysis Cross-Over Studies Disease Models, Animal Disorders of higher nervous function. Focal brain diseases. Central vestibular syndrome and deafness. Brain stem syndromes Dose-Response Relationship, Drug Double-Blind Method Electroencephalography Electromyography GABA Agonists - pharmacology GABA Agonists - therapeutic use Human subjects Humans Hypnotics and Sedatives - pharmacology Hypnotics and Sedatives - therapeutic use Insomnia Male Medical sciences Nervous system (semeiology, syndromes) Neurology Neuropharmacology Pharmacology Pharmacology. Drug treatments Polysomnography Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopharmacology Pyridines - pharmacology Rats Rats, Sprague-Dawley Reference Values Reproducibility of Results Rodents Serotonin Uptake Inhibitors - pharmacology Serotonin Uptake Inhibitors - therapeutic use Sleep - drug effects Sleep Initiation and Maintenance Disorders - chemically induced Sleep Initiation and Maintenance Disorders - physiopathology Sleep Initiation and Maintenance Disorders - prevention & control Telemetry Trazodone - pharmacology |
Title | A translational, caffeine-induced model of onset insomnia in rats and healthy volunteers |
URI | https://www.ncbi.nlm.nih.gov/pubmed/17225163 https://www.proquest.com/docview/218956203 https://www.proquest.com/docview/19640830 https://www.proquest.com/docview/70266783 |
Volume | 191 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swEBddC2MwRtt9Ze0yPYw-jJjJlizZTyMZDWXQEEYLeTP6sKDQOdnsPuS_352lxPShfbKN9QE66fST7u53hHxVqRWKp2mipNOJcAb0oNQmAWhqC6jEtcB45-uFvLoVv1b5KvrmtNGtcqcTe0Xt1hbvyL_DVgRQPmP8x-Zvgkmj0LgaM2i8IEfIXIYeXWqlBkUsMAYzfEgAAoGRmWM8WV7sLJysJxTNMMcBnq2lyhL2aI96vdEtDJcPeS6eBqL9hjQ_Jm8ikqTTIPoTclA3p-TldbSVn5KLZWCl3k7ozRBk1U7oBV0OfNXbt2Q1pR3uWPfxXnBCrfa-hkYSOLCD6B3t8-XQtafoe91RjBj709xpeKEwg1qqG0dDROWWor4DaQGsfEdu55c3P6-SmHAhsSLnXeIdl9zI1BfaOqEkq7UuYYR85kvlCq-1yZ0pGDelMc6pzPrcMw3r2Bdpah1_Tw6bdVN_JBTNo1mqlcgzLyScg31Z1kznJpV1CUp2RNhuiCsb2cgxKcZ9tedR7qVS9X53IJWKjci3fZVNoOJ4rvD4kdyGGkjgx5QckbOdIKu4bNtqP8lG5Mv-L6w3NKLopl4_tBUSmAFsZU-XUHCsBQgAbXwI82PoW4H2BAD86dm-z8ircIGMXpXn5LD791B_BuTTmXE_v8fkaDqfzRbwnF0ulr__A7WtAbM |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3fb9MwED6NTgIkhGD8KoPND7AH1AgnduzkAaEBmzq2VhXqpL4FO46lSSMtJBPqH8X_yDlOGu1he9tbotiOlLvcfefzfQfwToY5lywMAymMCrjRaAeF0gFC0zzBSUxxV-88mYrxOf--iBdb8K-rhXHHKjub2Bhqs8zdHvlHdEUI5SPKPq9-B65plEuudh00vFacFuu_GLFVn06-oXjfR9Hx0fzrOGibCgQ5j1kdWMME0yK0icoNl4IWSqXoKG1kU2kSq5SOjU4o06nWxsgot7GlCnXVJmGYG4br3oNtzjCSGcD2l6Pp7Edv-rmr-vQ3AqGH54BmroItTrqcKm0oTCPXVcFF80JGAb3mFR-tVIUCsr6zxs3Qt3GBx0_gcYtdyaFXtqewVZQ7cH_SZud34GDmebDXIzLvy7qqETkgs54he_0MFoekdj7yst2JHJFcWVvgIsFFaVDZDGk69JClJe60d01cjdqv8kLhBUGdrYgqDfE1nGviLCzqBwLZ53B-J9J4AYNyWRavgLiEbBQqyePIcoGRt03TgqpYh6JI0awPgXafOMtb_nPXhuMy2zA3N1LJmpN-KJWMDuHDZsrKk3_cNnjvmtz6GY4ykEoxhN1OkFlrKKpso9ZD2N88xT_cpW1UWSyvqsxRpiFQpjePkBhII-jANV56_ejfLdFeI-R-feu79-HBeD45y85Opqe78NBvX7sznW9gUP-5Kt4i7qr1XqvtBH7e9Q_2H40rPy4 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1RT9RAEJ4gJsSEGEXFE4V9UB7MNWy77W77YAwRLyBC7gGSe6u73W5Cgr3Dlpj7af47Z7rtNTzAG29t2t0mndmZb3dmvgH4qMIiViIMAyWtDmJr0A5KbQKEpkWKg4SOqd757FweX8Y_ZslsDf71tTCUVtnbxNZQ23lBZ-QH6IoQykdcHLguK2J6NPm6uAmogRQFWvtuGl5DTsvlX9y91V9OjlDUn6Jo8v3i23HQNRgIijgRTeCskMLI0KW6sLGSvNQ6Q6fpIpcpmzqtTWJNyoXJjLFWRYVLHNeoty4Nw8IKnPcJPFUiCWmJqZkanEBM9Z_-RiII8WzQgmrZkrSPrvKWzDSi_gq0r5cqCvgd_7i50DWKyvkeG_eD4NYZTl7A8w7FskOvdi9hray2YOOsi9Nvwf7UM2Ivx-xiKPCqx2yfTQeu7OUrmB2yhrzldXcmOWaFdq7ESYKryqLaWdb26mFzxyjvu2FUrfa7utJ4wVB7a6Yry3w155KRrUVNQUj7Gi4fRRZvYL2aV-VbYBSajUKt4iRyscQ9uMuykuvEhLLM0MCPgPe_OC86JnRqyHGdrzicW6nkbc4fSiXnI_i8GrLwNCAPvbx7R27DCCIP5EqOYKcXZN6ZjDpfKfgI9lZPca1TAEdX5fy2zok8DSEzv_8NhVtqhB84x7bXj-HbCi03gu93D357DzZwWeU_T85Pd-CZP8em5M73sN78uS0_IABrzG6r6gx-Pfba-g_0EkH- |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+translational%2C+caffeine-induced+model+of+onset+insomnia+in+rats+and+healthy+volunteers&rft.jtitle=Psychopharmacology&rft.au=Paterson%2C+Louise+M&rft.au=Wilson%2C+Sue+J&rft.au=Nutt%2C+David+J&rft.au=Hutson%2C+Peter+H&rft.date=2007-05-01&rft.pub=Springer+Nature+B.V&rft.issn=0033-3158&rft.eissn=1432-2072&rft.volume=191&rft.issue=4&rft.spage=943&rft_id=info:doi/10.1007%2Fs00213-006-0672-0&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=1231721161 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0033-3158&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0033-3158&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0033-3158&client=summon |